MX2020007431A - Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo. - Google Patents
Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo.Info
- Publication number
- MX2020007431A MX2020007431A MX2020007431A MX2020007431A MX2020007431A MX 2020007431 A MX2020007431 A MX 2020007431A MX 2020007431 A MX2020007431 A MX 2020007431A MX 2020007431 A MX2020007431 A MX 2020007431A MX 2020007431 A MX2020007431 A MX 2020007431A
- Authority
- MX
- Mexico
- Prior art keywords
- bone
- gremlin
- treatment
- inhibitor
- fracture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802486.9A GB201802486D0 (en) | 2018-02-15 | 2018-02-15 | Methods |
| PCT/EP2019/053726 WO2019158658A1 (en) | 2018-02-15 | 2019-02-14 | Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007431A true MX2020007431A (es) | 2020-09-14 |
Family
ID=61783877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007431A MX2020007431A (es) | 2018-02-15 | 2019-02-14 | Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11524997B2 (https=) |
| EP (1) | EP3752527A1 (https=) |
| JP (1) | JP7395485B2 (https=) |
| KR (1) | KR20200121833A (https=) |
| CN (1) | CN111683965B (https=) |
| AR (1) | AR114105A1 (https=) |
| AU (1) | AU2019220407B2 (https=) |
| BR (1) | BR112020015961A2 (https=) |
| CA (1) | CA3090404A1 (https=) |
| CL (2) | CL2020002040A1 (https=) |
| CO (1) | CO2020009731A2 (https=) |
| EA (1) | EA202091891A1 (https=) |
| GB (1) | GB201802486D0 (https=) |
| IL (1) | IL276491A (https=) |
| MX (1) | MX2020007431A (https=) |
| SG (1) | SG11202005735SA (https=) |
| WO (1) | WO2019158658A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| PL3806898T3 (pl) | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| CA3192306A1 (en) | 2020-10-20 | 2022-04-28 | Burkhard Ludewig | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
| EP4511395A1 (en) | 2022-04-20 | 2025-02-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| WO2024244941A1 (en) * | 2023-05-26 | 2024-12-05 | The University Of Hong Kong | Compositions and methods for the treatment of bone loss |
| WO2026027660A1 (en) | 2024-08-02 | 2026-02-05 | UCB Biopharma SRL | Formulations of anti-gremlin-1 antibodies |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1053002A1 (en) | 1998-02-10 | 2000-11-22 | Oregon Health Sciences University | Treatment of bony defects with osteoblast precursor cells |
| AU2002243495A1 (en) | 2001-01-12 | 2002-07-24 | University Of Medicine And Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US20120202710A1 (en) | 2003-09-09 | 2012-08-09 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| EP1571159A1 (en) * | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US20090203041A1 (en) | 2006-04-21 | 2009-08-13 | Wei Shi | Bmp4 inhibitors |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| WO2009040562A1 (en) | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| JP6339063B2 (ja) | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| ES2898620T3 (es) | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Anticuerpos humanos contra GREM 1 |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| PL3806898T3 (pl) | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
-
2018
- 2018-02-15 GB GBGB1802486.9A patent/GB201802486D0/en not_active Ceased
-
2019
- 2019-02-13 AR ARP190100349A patent/AR114105A1/es unknown
- 2019-02-14 WO PCT/EP2019/053726 patent/WO2019158658A1/en not_active Ceased
- 2019-02-14 AU AU2019220407A patent/AU2019220407B2/en active Active
- 2019-02-14 KR KR1020207026431A patent/KR20200121833A/ko not_active Ceased
- 2019-02-14 CA CA3090404A patent/CA3090404A1/en active Pending
- 2019-02-14 MX MX2020007431A patent/MX2020007431A/es unknown
- 2019-02-14 EP EP19706471.0A patent/EP3752527A1/en active Pending
- 2019-02-14 BR BR112020015961-1A patent/BR112020015961A2/pt unknown
- 2019-02-14 JP JP2020542852A patent/JP7395485B2/ja active Active
- 2019-02-14 SG SG11202005735SA patent/SG11202005735SA/en unknown
- 2019-02-14 CN CN201980012164.7A patent/CN111683965B/zh active Active
- 2019-02-14 EA EA202091891A patent/EA202091891A1/ru unknown
- 2019-02-14 US US16/970,391 patent/US11524997B2/en active Active
-
2020
- 2020-08-04 IL IL276491A patent/IL276491A/en unknown
- 2020-08-05 CL CL2020002040A patent/CL2020002040A1/es unknown
- 2020-08-06 CO CONC2020/0009731A patent/CO2020009731A2/es unknown
-
2021
- 2021-08-17 CL CL2021002176A patent/CL2021002176A1/es unknown
-
2022
- 2022-12-07 US US18/062,608 patent/US12240896B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019220407A1 (en) | 2020-08-27 |
| JP7395485B2 (ja) | 2023-12-11 |
| IL276491A (en) | 2020-09-30 |
| EP3752527A1 (en) | 2020-12-23 |
| CO2020009731A2 (es) | 2020-08-21 |
| BR112020015961A2 (pt) | 2020-12-15 |
| CA3090404A1 (en) | 2019-08-22 |
| CN111683965B (zh) | 2025-02-25 |
| AU2019220407B2 (en) | 2025-07-31 |
| JP2021513960A (ja) | 2021-06-03 |
| US20230174635A1 (en) | 2023-06-08 |
| US20210107973A1 (en) | 2021-04-15 |
| US12240896B2 (en) | 2025-03-04 |
| EA202091891A1 (ru) | 2020-10-29 |
| RU2020129443A (ru) | 2022-03-15 |
| US11524997B2 (en) | 2022-12-13 |
| CN111683965A (zh) | 2020-09-18 |
| SG11202005735SA (en) | 2020-07-29 |
| KR20200121833A (ko) | 2020-10-26 |
| GB201802486D0 (en) | 2018-04-04 |
| WO2019158658A1 (en) | 2019-08-22 |
| CL2020002040A1 (es) | 2020-12-18 |
| CL2021002176A1 (es) | 2022-04-22 |
| AR114105A1 (es) | 2020-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007431A (es) | Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto oseo. | |
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| EP3893733A4 (en) | Machine learning systems and methods for assessment, healing prediction, and treatment of wounds | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| PH12021551689A1 (en) | Cgrp antagonists for treating migraine breakthrough | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| EA201890728A2 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| EP4021360C0 (en) | APPARATUS AND SYSTEMS FOR THE TREATMENT OF DAMAGED TISSUE | |
| CR20210103A (es) | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| EP4065377C0 (fr) | Dispositif de traitement de plusieurs faces d'objets, et procédé de traitement correspondant | |
| BR112019024538A2 (pt) | composição para uso no tratamento de rosácea e método para tratar rosácea para um paciente | |
| EP4426682A4 (en) | SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| EP4531713A4 (en) | CARDIOVASCULAR TISSUE TREATMENT SYSTEMS AND METHODS | |
| EP3946366A4 (en) | METHODS AND DEVICES FOR TREATMENT OF POSTOPERATIVE LAXITY OF TENDONS AND TENDONS REPAIR | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer | |
| WO2019115493A3 (en) | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain | |
| MX2020013100A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| PL441996A1 (pl) | Wielofunkcyjny, hydrożelowy materiał hybrydowy, w szczególności do stosowania w leczeniu ubytków kostnych oraz sposób jego otrzymywania | |
| MX2025002182A (es) | Terapias de combinacion que usan inhibidores de proteina arginina n-metil transferasa 5 (prmt5) e inhibidores de la familia del oncogen de linfoma de celulas b 2 (bcl-2) para el tratamiento del cancer | |
| MX2024015040A (es) | Fitusiran para el tratamiento de la hemofilia a y b en pacientes pediatricos |